Product news

Share this article:
Novartis and Medicines for Malaria Venture have launched a new pediatric formulation of the malaria treatment Coartem. The product, Coartem Dispersible, is the first artemisinin-based combination therapy (ACT) developed specifically for children, according to a company statement. Novartis will offer the product without profit for public sector use in malaria-endemic regions of Africa.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.